We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+9.36%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$377M
AUM Growth
-$132M
Cap. Flow
-$52M
Cap. Flow %
-13.79%
Top 10 Hldgs %
59.97%
Holding
58
New
11
Increased
13
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
TARA icon
Protara Therapeutics
TARA
+$64.2M
2
ETON icon
Eton Pharmaceutcials
ETON
+$12.7M
3
MTEM
Molecular Templates, Inc.
MTEM
+$7.79M
4
MYOV
Myovant Sciences Ltd.
MYOV
+$7.36M
5
KALA icon
KALA BIO
KALA
+$5M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$34.1M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$21.2M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$17.5M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$13.9M
5
AXGN icon
Axogen
AXGN
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
2 Miscellaneous 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
1
Protara Therapeutics
TARA
$236M
$52.1M 13.82%
2,208,472
+2,203,768
+46,849% +$64.2M
FTSV
2
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$36.8M 9.75%
385,500
-176,500
-31% -$10.7M
OCUL icon
3
Ocular Therapeutix
OCUL
$2.38B
$25.4M 6.72%
5,122,500
+15,000
+0.3% +$74.1K
APTO
4
DELISTED
Aptose Biosciences, Inc.
APTO
$23.9M 6.33%
8,938
-140
-2% -$418K
NGNE icon
5
Neurogene
NGNE
$758M
$15.9M 4.22%
70,000
+935
+1% +$192K
CDXS icon
6
Codexis
CDXS
$182M
$15.6M 4.14%
1,400,000
– –
EIDX
7
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$15.5M 4.1%
315,550
– –
ETON icon
8
Eton Pharmaceutcials
ETON
$1.79B
$14.9M 3.95%
3,640,000
+2,170,544
+148% +$12.7M
CCXI
9
DELISTED
ChemoCentryx, Inc.
CCXI
$14.5M 3.85%
361,600
– –
STXS icon
10
Stereotaxis
STXS
$147M
$11.7M 3.09%
3,861,500
-251,000
-6% -$1.04M
QURE icon
11
uniQure
QURE
$3.44B
$9.96M 2.64%
210,000
– –
ODT
12
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$9.94M 2.63%
360,000
+5,000
+1% +$146K
HROW icon
13
Harrow
HROW
$1.44B
$9.55M 2.53%
2,500,000
+160,000
+7% +$948K
ATXI
14
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$9.25M 2.45%
920
– –
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$9.14M 2.42%
222,000
-2,500
-1% -$139K
XOMA
16
DELISTED
Xoma
XOMA
$7.88M 2.09%
387,000
+13,550
+4% +$313K
KALA icon
17
KALA BIO
KALA
$15.7M
$7.23M 1.92%
+313
New +$5M
MTEM
18
DELISTED
Molecular Templates, Inc.
MTEM
$7.09M 1.88%
+35,560
New +$7.79M
AVTX icon
19
Avalo Therapeutics
AVTX
$1.08B
$5.46M 1.45%
765
+4
+0.5% +$42.3K
CRNX icon
20
Crinetics Pharmaceuticals
CRNX
$9B
$5.42M 1.44%
368,750
+102,650
+39% +$2.1M
KYNB
21
Kyntra Bio
KYNB
$32.4M
$5.07M 1.34%
5,840
– –
FOCL
22
EDAP TMS S.A.
FOCL
$199M
$4.98M 1.32%
2,193,500
+408,500
+23% +$1.44M
MYOV
23
DELISTED
Myovant Sciences Ltd.
MYOV
$4.95M 1.31%
+656,000
New +$7.36M
TGTX icon
24
TG Therapeutics
TGTX
$8.53B
$4.85M 1.29%
493,000
-86,651
-15% -$1.09M
KDMN
25
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.83M 1.28%
1,152,250
+211,877
+23% +$912K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2020 Portfolio in Review

As of Q1 2020, Opaleye Management held 58 positions worth $377M, down 26% from $510M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Opaleye Management withdrew a net $52M in Q1 2020, closing 14 positions and reducing 12 holdings. Its most notable exit was Epizyme, Inc, an estimated $34.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Molecular Templates, Inc. worth $7.09M.

  • Opaleye Management's largest Q1 2020 buy was Molecular Templates, Inc.: 35,560 shares worth $7.09M.
  • Opaleye Management added most to Protara Therapeutics in Q1 2020, an estimated $64.2M increase.
  • Opaleye Management's biggest Q1 2020 reduction was Forty Seven, Inc. Common Stock, cutting an estimated $10.7M.
  • Opaleye Management fully exited Epizyme, Inc in Q1 2020, selling an estimated $34.1M.
  • Opaleye Management's ten largest holdings make up 60% of its $377M portfolio in Q1 2020.
  • Opaleye Management opened 11 new positions and closed 14 in Q1 2020.
  • Opaleye Management's portfolio value fell 26% quarter-over-quarter to $377M.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.